Deutsche Bank Maintains Buy Rating on Allergen (AGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to Deutsche Bank Maintains Buy Rating on Allergen (AGN)
October 27, 2014 9:12 AM EDT
Allergan, Inc. (NYSE: AGN) today issued the following statement in response to Valeant Pharmaceuticals International (NYSE: VRX) October 27, 2014 letter to the Allergan Board of Directors.
Delivering value to Allergans stockholders remains the Boards highest priority. If Valeant were to make an increased offer, the Board would carefully consider it and respond in due course. However, to date, as we have noted repeatedly, Valeants... More
October 27, 2014 7:02 AM EDT
Allergan (NYSE: AGN) reported Q3 EPS of $1.78, $0.10 better than the analyst estimate of $1.68. Revenue for the quarter came in at $1.79 billion versus the consensus estimate of $1.78 billion.
Allergan sees FY2014 EPS of $6.27-$6.30, versus the consensus of $6.12. Allergan sees FY2014 revenue of $7.08-7.155 billion,... More
